When:
Time: 8:00am PDT, 11:00am EDT, 4:00pm BST, 5:00pm CEST
Duration: 60 minutes
Pharmaceutical organizations have a problem – there is a growing volume of safety data in varied data sources, report types, formats, etc. This is leading to unsustainable increases in the costs of safety operations and safety assessment, and leaders are looking for innovative solutions from new AI, automation and cloud approaches. A recent Gartner reported stated: “By 2023, 60% of the top 100 life science companies will use AI augmentation in one or more safety vigilance solutions”.[1]
Many of our customers are using the power of IQVIA’s Natural Language Processing (NLP) platform from Linguamatics, to optimize their safety processes, and lower development costs. NLP transforms unstructured text into structured data that can be rapidly analyzed or visualized. This capability can be applied for safety assessment and medical review, enabling effective search of literature, drug labels and regulatory review packages for adverse events and the critical context around these, to help with a deeper understanding and contextualization of any potential safety signal.
Join this webinar to hear customer success stories, and be one of the first to see a demo of our new safety intelligence hub.
What will you learn?
- How natural language processing (NLP) text mining can extract structured data from unstructured text for safety case processing, MedDRA mapping, safety intelligence, contextualization of safety signals.
- How big pharma access internal data silos and external data sources for safety decision making. Use cases from top pharma and the FDA will be discussed.
Who should attend?
- Teams involved in adverse event medical coding, safety systems, medical literature mining for safety intelligence.
- With an interest in getting better value from both internal and external textual information and integrating diverse data sets to provide knowledge relevant to drug safety and risk prediction.
- Informaticians, information professionals, researchers, with responsibility for:
- Risk profiles for targets in early drug discovery
- Preclinical and clinical drug safety
- Safety assessment across the pipeline
References:
[1] Jeff Smith, “Life Science CIOs Reduce Runaway Costs With Innovative Safety Vigilance Technology”. March 2021
Speakers
Jane Reed
Director, Life ScienceJane Reed
Jane Reed is Director of Life Science at Linguamatics. She is responsible for developing the strategic vision for Linguamatics’ growing product portfolio and business development in the life science domain. Jane has extensive experience in life science informatics. She worked for more than 15 years in vendor companies supplying data products, data integration and analysis, and consultancy to pharma and biotech—with roles at Instem, BioWisdom, Incyte, and Hexagen. Before moving into the life science industry, Jane worked in academia with post-docs in genetics and genomics.
Sridevi Krishnamurthy
Application ScientistSridevi Krishnamurthy
Sridevi joined Linguamatics as an Application Scientist in 2019. In this role, Sridevi is responsible for applying NLP techniques to a variety of different data sources to derive insights and help customers find answers to their questions in a much more efficient manner.
